A Study of Nipocalimab in Adult Participants With Active Lupus Nephritis

Conditions

Placebo — OTHER
Placebo will be administered intravenously.
Nipocalimab — DRUG
Nipocalimab dose 1 and dose 2 will be administered intravenously.
Standard-of-care treatment — DRUG
Standard-of-care treatment including MMF or MPA and glucocorticoids will be administered intravenously through Week 52.

The purpose of this study is to evaluate the efficacy of nipocalimab versus placebo in participants with active Lupus Nephritis (LN).

Placebo Comparator: Group 1: Placebo
Participants will receive placebo intravenously (IV) every two weeks (q2w) from Week 0 through Week 50 along with standard-of-care treatment of mycophenolate mofetil (MMF) or mycophenolic acid (MPA) and glucocorticoid. Participants who will complete the assessments at Week 52 and have achieved complete renal response (CRR) may have the option to participate in the long-term extension (LTE) until unblinding of the study.
Experimental: Group 2: Nipocalimab Dose 1
Participants will receive nipocalimab dose 1 IV q2w from Week 0 through Week 50 along with standard-of-care treatment of MMF or MPA and glucocorticoid. Participants who will complete the assessments at Week 52 and have achieved CRR may have the option to participate in the LTE of the study.
Experimental: Group 3: Nipocalimab Dose 2
Participants will receive nipocalimab dose 2 IV q2w from Week 0 through Week 50 along with standard-of-care treatment of MMF or MPA and glucocorticoid. Participants who will complete the assessments at Week 52 and have achieved CRR may have the option to participate in the LTE of the study.

Percentage of Participants Achieving Complete Renal Response (CRR) [ Time Frame: Week 52 ]